BUZZ-Larimar jumps on FDA's 'breakthrough' tag for neurological disorder therapy** Shares of therapy developer Larimar Therapeutics LRMR.O jump 32% to $3.71 premarket
** Co says the U.S. FDA granted a breakthrough designation for its experimental therapy nomlabofusp
** A breakthrough therapy tag is meant to speed up development and review of drugs to treat a serious condition or unmet medical need
** Nomlabofusp is a protein replacement therapy for the treatment of adults and children with the neurodegenerative disorder, Friedreich's ataxia
** Co plans to submit marketing application for nomlabofusp by June
** Up to last close, stock down 26.3% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments